Zibotentan + Placebo oral tablet
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Microvascular Angina
Conditions
Microvascular Angina
Trial Timeline
Oct 18, 2019 → Jun 8, 2023
NCT ID
NCT04097314About Zibotentan + Placebo oral tablet
Zibotentan + Placebo oral tablet is a phase 2 stage product being developed by AstraZeneca for Microvascular Angina. The current trial status is completed. This product is registered under clinical trial identifier NCT04097314. Target conditions include Microvascular Angina.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04097314 | Phase 2 | Completed |
Competing Products
7 competing products in Microvascular Angina
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lercanidipine + Valsartan + Nicorandil + Doxazosin + Moxonidin + Pindolol + Amiloride, hydrochlorothiazide | Novartis | Pre-clinical | 23 |
| Ranolazine + Placebo | Gilead Sciences | Approved | 84 |
| Ranolazine + Placebo | Gilead Sciences | Phase 2 | 51 |
| Temanogrel + Placebo | Pfizer | Phase 2 | 51 |
| SAR247799 + Placebo + Sildenafil + Acetylcholine | Sanofi | Phase 1 | 32 |
| SAR407899 + Placebo + Adenosine + Regadenoson + 13N-ammonia + 82Rubidium | Sanofi | Phase 2 | 51 |
| Felzartamab + Placebo | Biogen | Phase 2 | 49 |